CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $214,000 | +25.9% | 7,768 | +54.8% | 0.00% | – |
| Q2 2023 | $170,000 | +80.9% | 5,019 | +92.2% | 0.00% | – |
| Q1 2023 | $94,000 | -60.8% | 2,612 | -51.5% | 0.00% | – |
| Q4 2022 | $240,000 | +1311.8% | 5,381 | +807.4% | 0.00% | – |
| Q3 2022 | $17,000 | +112.5% | 593 | +96.4% | 0.00% | – |
| Q2 2022 | $8,000 | -91.7% | 302 | -89.3% | 0.00% | – |
| Q1 2022 | $96,000 | -73.9% | 2,829 | -70.4% | 0.00% | – |
| Q4 2021 | $368,000 | +31.4% | 9,544 | +84.0% | 0.00% | – |
| Q3 2021 | $280,000 | +211.1% | 5,187 | +93.3% | 0.00% | – |
| Q2 2021 | $90,000 | +2150.0% | 2,684 | +995.5% | 0.00% | – |
| Q4 2020 | $4,000 | – | 245 | +1784.6% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 13 | -95.2% | 0.00% | – |
| Q2 2020 | $3,000 | +50.0% | 272 | -80.9% | 0.00% | – |
| Q1 2020 | $2,000 | +100.0% | 1,427 | +194.2% | 0.00% | – |
| Q4 2019 | $1,000 | 0.0% | 485 | -14.8% | 0.00% | – |
| Q3 2019 | $1,000 | – | 569 | +4276.9% | 0.00% | – |
| Q2 2019 | $0 | – | 13 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 13 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |